News

FDA Approval

FDA Approves Pembrolizumab for Patients With HER2-Positive, PD-L1 Expressing Gastric or Gastroesophageal Junction Adenocarcinoma

03/19/2025

Stephanie Holland

Based on results from the KEYNOTE-811 study, the FDA has approved first-line pembrolizumab plus trastuzumab, fluoropyrimidine, and platinum-containing chemotherapy for patients with locally advanced, unresectable, or metastatic HER2-positive...

Based on results from the...

03/19/2025

Oncology

Videos

Nivolumab Plus Ipilimumab Combination for Microsatellite Instability-High, Mismatch Repair-Deficient Metastatic Colorectal Cancer

02/04/2025

Thierry André, MD

Thierry Andre, MD, describes results from the CheckMate 8HW trial which evaluated nivolumab plus ipilimumab compared with nivolumab monotherapy among patients with MSI-H/dMMR metastatic colorectal cancer.

Thierry Andre, MD, describes...

02/04/2025

Oncology

News

Perioperative Chemotherapy Improves Survival for Patients with Resectable Esophageal Cancer

01/29/2025

Stephanie Holland

According to results from a phase 3 study, perioperative chemotherapy improved survival compared to preoperative chemoradiotherapy among patients with resectable esophageal cancer.

According to results from a...

01/29/2025

Oncology

Xuefeng Leng, MD, PhD, Sichuan Cancer Hospital & Institute

Videos

Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Esophageal Squamous Cell Carcinoma

01/28/2025

Xuefeng Leng, MD, explains results from the phase 3 SCIENCE trial, evaluating neoadjuvant chemoradiotherapy and chemotherapy with sintilimab for esophageal squamous cell carcinoma.

Xuefeng Leng, MD, explains...

01/28/2025

Oncology

Anna Martling, MD, Karolinska Institutet

Videos

Aspirin Reduced Risk of CRC Recurrence for Patients With PI3K Alterations

01/28/2025

Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.

Anna Martling, MD, PhD,...

01/28/2025

Oncology

Conference Coverage

Addition of Evorpacept Shows Promise for Patients With HER2-Positive Gastric or Gastroesophageal Junction Cancer

01/24/2025

Allison Casey

According to the phase 2 ASPEN-06 results, the addition of evorpacept to trastuzumab, ramucirumab, and paclitaxel showed promise for patients with HER2-positive gastric or gastroesophageal junction cancer.

According to the phase 2...

01/24/2025

Oncology

Conference Coverage

Neoadjuvant Chemoradiotherapy With or Without Sintilimab for Advanced Esophageal Squamous Cell Carcinoma

01/24/2025

Allison Casey

According to the phase 3 SCIENCE trial, neoadjuvant chemoradiotherapy with or without sintilimab significantly improved pathological complete response rates compared with neoadjuvant chemotherapy with sintilimab for patients with esophageal...

According to the phase 3 SCIENCE...

01/24/2025

Oncology

Conference Coverage

Addition of Trastuzumab to Chemotherapy for HER2-Positive Gastric Cancers

01/24/2025

Allison Casey

According to results from a phase 2 trial, following the amendment of chemotherapy regimen to FLOT, the addition of trastuzumab with or without pertuzumab did not improve progression-free survival or overall survival for patients with...

According to results from a...

01/24/2025

Oncology

Conference Coverage

NALIRIFOX Dose Reductions Maintain Overall Survival in Metastatic Pancreatic Cancer

01/23/2025

Allison Casey

According to an exploratory analysis of the NAPOLI 3 trial, dose reductions of liposomal irinotecan or oxaliplatin did not negatively impact the overall survival among patients with metastatic pancreatic ductal adenocarcinoma.

According to an exploratory...

01/23/2025

Oncology

News

FDA Grants Accelerated Approval for Encorafenib for BRAF V600E Mutant Metastatic Colorectal Cancer

12/20/2024

Allison Casey

On December 20, 2024, the US FDA granted an accelerated approval for encorafenib plus cetuximab and modified FOLFOX6 for patients with metastatic colorectal cancer with a BRAF V600E mutation.

On December 20, 2024, the US FDA...

12/20/2024

Oncology

Recent News

News

Modakafusp Alfa Demonstrates Antitumor Activity Among Patients With Relapsed/Refractory Multiple Myeloma

04/02/2025

Emily Estrada

At a tolerable and safe dose, the anti-CD38 antibody, modakafusp alfa demonstrated decreased tumor activity and immune activation among patients with relapsed/refractory multiple myeloma.

At a tolerable and safe dose,...

04/02/2025

Oncology

News

Quadruplet Therapy Demonstrates Efficacy for Treatment of Transplant-Ineligible Newly Diagnosed Multiple Myeloma

04/02/2025

Emily Estrada

Quadruplet therapy with isatuximab, weekly bortezomib, lenalidomide, and limited dexamethasone demonstrated safety and efficacy for older patients with transplant-ineligible MM in a phase 2 clinical trial.

Quadruplet therapy with...

04/02/2025

Oncology

News

Co-Occurrence of High-Risk Cytogenetic Abnormalities as a Predictive Marker for Multiple Myeloma

04/02/2025

Emily Estrada

The presence of 2 or more high-risk cytogenetic abnormalities among patients with multiple myeloma was associated with poor survival outcomes, according to a systematic review and meta-analysis.

The presence of 2 or more...

04/02/2025

Oncology

News

Pembrolizumab Plus Bevacizumab Shows Promise Among Previously Untreated Patients With Melanoma Brain Metastases

04/01/2025

Stephanie Holland

According to results from a phase 2 study, pembrolizumab plus bevacizumab demonstrated promise among previously untreated patients with melanoma brain metastases.

According to results from a...

04/01/2025

Oncology

News

Outcomes Without Adjuvant Radioactive Iodine Among Pediatric Patients With Papillary Thyroid Cancer

04/01/2025

Allison Casey

According to a retrospective cohort study, omitting adjuvant radioactive iodine therapy for pediatric patients with papillary thyroid cancer did not compromise outcomes.

According to a retrospective...

04/01/2025

Oncology

News

Lenvatinib Plus High-Dose Radioiodine Therapy Shows Promise for Patients With Metastatic Well-Differentiated Thyroid Cancer

04/01/2025

Allison Casey

A study found the addition of lenvatinib to high-dose radioiodine therapy showed promise in improving response for patients with metastatic well-differentiated radioiodine-avid thyroid cancer.

A study found the addition of...

04/01/2025

Oncology

News

Zenocutuzumab Demonstrates Durable Activity in NRG1 Fusion–Positive Solid Tumors

03/31/2025

Janelle Bradley

Findings from a phase 2 study show zenocutuzumab demonstrated durable clinical activity and a favorable safety profile in patients with NRG1 fusion–positive solid tumors, particularly non–small-cell lung and pancreatic cancers.

Findings from a phase 2 study...

03/31/2025

Oncology

FDA Approval

Durvalumab Approved for Muscle Invasive Bladder Cancer

03/31/2025

Allison Casey

The US FDA approved neoadjuvant durvalumab plus gemcitabine-cisplatin followed by adjuvant durvalumab after radical cystectomy for patients with muscle invasive bladder cancer.

The US FDA approved neoadjuvant...

03/31/2025

Oncology

FDA Approval

FDA Expands Approval of Lutetium Lu 177 Vipivotide Tetraxetan for Metastatic Castration-Resistant Prostate Cancer

03/28/2025

Stephanie Holland

Based on results from the PSMAfore trial, the FDA has expanded the approval of lutetium Lu 177 vipivotide tetraxetan to include patients with PSMA-positive metastatic castration-resistant prostate cancer previously treated with ARPIs and...

Based on results from the...

03/28/2025

Oncology

FDA Approval

FDA Approves Cabozantinib for Patients With Locally Advanced or Metastatic Well-Differentiated pNETs and epNETs

03/26/2025

Stephanie Holland

Based on results from the CABINET trial, the FDA has approved cabozantinib for patients 12 years of age and older with unresectable locally advanced or metastatic well-differentiated pNETs and epNETs who experienced disease progression after...

Based on results from the...

03/26/2025

Oncology